Use of in vitro-in vivo correlation (IVIVC) to facilitate the development of polymer-based controlled release injectable formulations

Recent Patents on Drug Delivery and Formulation

Volumn 4, Issue 2, 2010, Pages 94-104

  Mitra, Amitava ^a   Wu, Yunhui ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

In vitro release; IVIVC; Mathematical model; Microsphere; Patents

Indexed keywords

ANGIOPEPTIN; ARESTIN; BUSERELIN; BUSERELIN ACETATE; DEXAMETHASONE; EXENDIN 4; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUPERZINE A; HUPERZINE B; LEUPRORELIN; LYSOZYME; MACROGOL; METHADONE; MICROSPHERE; MINOCYCLINE; NALTREXONE; OCTREOTIDE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RISPERIDONE; SOMATULINE DEPOT; TRIPTORELIN; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; ALCOHOLISM; ARTICLE; BIODEGRADABILITY; CONTROLLED RELEASE FORMULATION; CORRELATIONAL STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; ENDOMETRIOSIS; GROWTH RETARDATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; NONHUMAN; PARTICLE SIZE; PATENT; PERIODONTITIS; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; SCHIZOPHRENIA; TREATMENT INDICATION;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INJECTIONS; MODELS, THEORETICAL; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; POLYMERS; REPRODUCIBILITY OF RESULTS;

EID: 77954073585     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221110791185024     Document Type: Article

References (63)

1. Burgess DJ, Hickey AJ. Microsphere technology and applications; Encyclopedia of pharmaceutical technology. In: Swarbrick J, Boylan JC, Eds. New York: Marcel Dekker 1994: 1-29.
2. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12(1): 1-99.
3. Miyajima M, Koshika A, Okada H, Ikeda M. Mechanism of drug release from poly(L-lactic acid) matrix containing acidic or neutral drugs. J Control Release 1999; 60: 199-209.
4. Faisant N, Siepmann J, Benoit JP. PLGA-based microparticles: Elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci 2002; 15: 355-66.
5. Allison SD. Analysis of initial burst in PLGA microspheres. Expert Opin Drug Deliv 2008; 5: 615-28.
6. Anderson JA, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
7. Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/ in vivo (bioavailability) correlations. J Control Release 2001; 72: 127-32.
8. US Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry. Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations 1997.
9. Cardot JM, Beyssac E, Alric M. in vitro-in vivo Correlation: Importance of dissolution in IVIVC. Dissolution Technol 2007; 2: 15-9.
10. Cardot JM, Beyssac E. in vitro/in vivo Correlation: Scientific implications and standardizations. Eur J Drug Met Pharmacokinet 1993; 18: 113-20.
11. Buchwald P. Direct differential equation based in vitro in vivo correlation (IVIVC) method. J Pharm Pharmacol 2003; 55: 495-504.
12. Herben VM, Huinink TB, Schot WW, Hudson I, Beijnen JH. Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anti-Cancer Drugs 1998; 9: 411-8.
13. Burgess DJ, Ed. Injectable dispersed systems: Formulation, processing and performance. Taylor Francis Group: Boca Raton, FL 2005.
14. Cleland JL. Protein delivery from biodegradable micropsheres. In: Sanders LM, Hendren RW, Eds. protein delivery: Physical Systems. New York: Plenum Press 1997: 1-41.
15. Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997; 28: 43-70.
16. Okada, H., Inoue, Y., Ogawa, Y. Prolonged release microcapsules. US5480656 (1994).
17. Kamei, S., Yamada, M., Ogawa, Y. Method of producing sustained-release microcapsules. US5575987 (1995).
18. [18] Pharmacircle website. www.pharmacircle.com
19. Lee, J.Y., Seo, M.H., Choi, I.J., Kim, J.H., Pai, C.M. Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof. US6193994 (1999).
20. Reslow, M., Jönsson, M., Larsson, K., Laakso, T. Microparticles. US6936278 (2002).
21. Joabsson, F., Johnsson, M., Tiberg, F. Glp-1 analogue formulations. US2006146490 (2006).
22. Okada, H., Inoue, Y., Ogawa, Y. Prolonged release microcapsules. US5643607 (1995).
23. Steber, W. Stable compositions for parenteral administration and method of making same. US5213810 (1990).
24. Ramstack, J.M., Herbert, P.F., Strobel, J., Atkins, T.J. Preparation of biodegradable microparticles containing a biologically active agent. US5650173 (1997).
25. Bodmer, D., Fong, J.W., Kissel, T., Maulding, H.V., Nagele, O., Pearson, J.E. Sustained release formulations of water soluble peptides. US5639480 (1995).
26. Pellet, M., Roume, C. Sustained release compositions and the process for their preparation. US6475507 (2000).
27. Pellet, M., Roume, C. Sustained-release compositions and method for preparing same. US6217893 (1999).
28. Orsolini, P. Method for preparing a pharmaceutical composition in the form of microparticles. US5134122 (1990).
29. Orsolini, P. Pharmaceutical composition in the form of microparticles. US5225205 (1992).
30. Tice, T.R., Staas, J.K., Ferrell, T.M. Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol. US6306425 (2000).
31. Brunner A, Mader K, Gopferich A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm Res 1999; 16: 847-53.
32. Faisant N, Akiki J, Siepmann F, Benoit JP, Siepmann J. Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory. Int J Pharm 2006; 314(2): 189-97.
33. Wischke C, Schwendeman SP. Principles of encapsulating hydro- phobic drugs in PLA/PLGA microparticles. Int J Pharm 2008; 364(2): 298-327.
34. D'Souza SS, DeLuca PP. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 2006; 23: 460-74.
35. Washington C. Drug release from microdisperse systems: A critical review. Int J Pharm 1990; 58: 1-12.
36. st ed. New York: Lippincott, Williams & Wilkins 2005; 672-88.
37. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: Workshop report. AAPS PharmSci 2002; 4: 1-11.
38. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: AAPS Workshop Report, Co-Sponsored by FDA and USP. Pharm Res 2002; 19: 1761-8.
39. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS Pharm Sci 2004; 6: 1-12.
40. Zolnik BS, Leary PE, Burgess DJ. Elevated temperature acce- lerated release testing of PLGA microspheres. J Control Release 2006; 112: 293-300.
41. Chidambaram N, Burgess DJ. A novel in vitro release method for submicronsized dispersed systems. AAPS Pharm Sci 1999; 1: E11.
42. Wang J, Flanagan DR. General solution for diffusion-controlled dissolution of spherical particles. 2. evaluation of experimental data. J Pharm Sci 2002; 91: 534-42.
43. Zolnik BS, Raton JL, Burgess DJ. Application of USP Apparatus 4 and in situ fiber optic analysis to microsphere release testing. Dissolution Technol 2005; 12: 11-4.
44. Zolnik BS, Burgess DJ. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 2008; 127: 137-45.
45. Chu DF, Fu XQ, Liu WH, Liu K, Li YX. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded PLGA microspheres in dogs. Int J Pharm 2006; 325: 116-23.
46. Conti B, Genta I, Giunchedi P, Modena T. Testing of in vitro dissolution behaviour of microparticulate drug delivery systems. Drug Dev Ind Pharm 1995; 21: 1223-33.
47. Zolnik BS, Burgess DJ. in vitro-in vivo Correlation on parenteral dosage forms. In: Biopharmaceutics applications in drug develop- ment. In: Krishna R, Yu L, Eds. New York: Springer 2008: 336-58.
48. Laurencin CT, Elgendy H. The biocompatibility and toxicity of biodegradable polymeric materials: Implications for drug delivery. In: Polymeric site-specific pharmacotherapt. In: Domb AJ, Ed. New York: John Wiley & Sons 1994: 27-46.
49. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: Focus on brain biocompatibility. Biomaterials 2003; 24(19): 3311-31.
50. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994; 105: 189-207.
51. Wagner JG, Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci 1963; 52: 610-1.
52. Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968; 57: 918-28.
53. Parojci J, Ibri S, Djuri Z, Jovanovi M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur J Pharm Sci 2007; 30: 264-72.
54. Gillespie WR. Convolution-based approaches for in vivo-in vitro correlation modeling. In: Young D, Devane JG, Butler J, Eds. In vitro in vivo correlations. Advances in experimental medicine and biology. New York: Plenum 1997: 423: 53-65.
55. Riley KF, Hobson MP, Bence SJ. Mathematical methods for physics and engineering. A comprehensive guide. Cambridge Univ Press: Cambridge 1997.
56. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. In vivo- in vitro Correlation (IVIVC) modeling incorporating a convolution step. J Pharmacokinet Pharmacodyn 2001; 28: 277-98.
57. Rossenu S, Gaynor C, Vermeulen A, Cleton A, Dunne A. A nonlinear mixed effects IVIVC model for multi-release drug delivery systems. J Pharmacokinet Pharmacodyn 2008; 35: 423-41.
58. Negrin CM, Delgado A, Llabres M, Evora C. in vivo-in vitro Study of biodegradable methadone delivery systems. Biomaterials 2001; 22: 563-70.
59. Blanco-Prieto MJ, Campanero MA, Besseghir K, Heimgatner F, Gander B. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release 2004; 96: 437-48.
60. Kostanski JW, DeLuca PP. A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS Pharm Sci Tech 2000; 1: article 4.
61. Heya T, Mikura Y, Nagai A, Miura Y, Futo T, Tomida Y, et al. Controlled release of thyrotropin releasing hormone from microspheres: Evaluation of release profiles and pharma-cokinetics after subcutaneous administration. J Pharm Sci 1994; 83: 798-801.
62. Jiang G, Woo BH, Kang F, Singh J, DeLuca PP. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(D, L,-lactideco-glycolide) micro- spheres. J Control Release 2002; 79: 137-45.
63. Morita T, Sakamura Y, Horikiri Y, Suzuki T, Yoshino H. Evaluation of in vivo release characteristics of protein-loaded biodegradable microspheres in rats and severe combined immu- nodeficiency disease mice. J Control Release 2001; 73: 213-21.